Ann: Notice of Annual General Meeting/Proxy Form , page-101

re: Ann: Notice of Annual General Meeting/Pro... Hi BB.

"Nice post abdm, agreed totally the science here is robust. The commercialisation of the science is the challenge - particularly under the prevailing global economic climate -but I'm with you it will happen."

I believe there is a small chance that the commercialisation strategy may have hit some obstacles with the FDA in 2011 - I have never assumed a direct connection with OBJ, however I was a little surprised after obtaining certain info publicly available from the FDA early in 2011 when soon after OBJ also made an announcement relating to international regulatory delays with regards to assessment of biomaterials?

05/04/2011: Shareholder Update
The Strategic Alliance with a major international FMCG company announced in September 2010 is progressing across multiple fronts. The broad range of products for which the OBJ technology is being evaluated has required the establishment of a number of new and innovative test models and the recruitment of leading specialists and industry experts familiar with these product categories. Various regulatory pre-requisites in different parts of the world have introduced additional regulatory requirements which the Company is now addressing.

27/09/2011: 2011 Annual Report
The Company also signed a letter of intent with one of the world’s largest Consumer Healthcare and Homecare product companies. Subject to an initial testing program, the companies intend working together in the design and development of suitable evaluation methodologies for specific active ingredients with the view to achieving commercially significant level of enhancements using OBJ’s technologies. These programs have progressed well after initial regulatory delays in accessing certain biomaterials.

After reading your post this morning I've been trying to track down a formal document I found early in 2011 which was addressed to the FDA from a "wireless device consortium" headed up by P&G. I'm sure you are well aware how powerful and politically motivated the FDA is, however I have never seen a document so demeaning in content towards the FDA in my life. In this instance it certainly left absolutely no doubt in my mind who was wearing the pants between these two power houses. I will continue to try and locate this document because although it doesn't provide any direct link to OBJ, any OBJ holder who can appreciate the power and respect that the FDA command from the biotech / pharmaceutical industry, will most definitely get some feeling of inspiration by the respect the world's largest consumer goods company, and OBJ's exclusive joint development partner clearly demands from all who conduct business with them.

The "prevailing global economic climate" however remains one of my bullish reasons for committing quite heavily into this stock. If the world economy wasn't looking so bleak I really do not know if I would be invested in OBJ today, and I can certainly confirm that if all the worlds economic issues magically recovered tomorrow I would become an extremely nervous holder of OBJ for the very first time. I truly believe the mounting global health crisis falls directly in the path of the boards long term business strategy - My opinion on this subject has never altered ;)

"Innovative technologies that are able to deliver drugs with a broader spectrum of characteristics are poised to revolutionize the transdermal drug delivery market and drive significant growth" - Source

"Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, antibodies and anti aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localised delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin’s natural barrier effect can be overcome. OBJ is the first company to create a broad spectrum through-the skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world."
__________

Hi MG,

For whatever it may or may not mean to you I wish to make a correction/change to the following statement made by myself a couple of days ago:

"Another point worth considering is that global giants like GSK and P&G are truly massive corporations, and the deal negotiation processes with companies of this magnitude would be slow and protracted. Liquidia Technologies announced its licensing deal with GSK over 4 months ago, and to my understanding they are still awaiting upfront payment."

My "understanding" was based on the fact that the upfront payment by GSK would enable Liquidia Technologies to hire up to an additional 10 staff as noted in this article, however until last night Liquidia had still not advertised any new positions. The following were posted by Liquidia Technologies last night:

I will continue to accept that any potential connection with Liquidia and OBJ is based on speculation only as there exists no formal connection between the two companies. However for the benefit of anyone else who may be interested, Liquidia like OBJ also specializes in innovative drug delivery technologies. The TEDMED conference presentation which I have posted again (for those interested) provides some insight to Liquidia's Print Technology platform from its CEO, Dr Joseph DeSimone.

Coincidentally, or not Dr DeSimone has signed a collaboration agreement with P&G in 2011, as provided below which remains highly confidential, and in June this year have also signed a licensing agreement with GSK. Some may recall in April this year that OBJ announced the expansion of its collaboration with GSK to, "GSK Pharmaceutical groups in the US" and Liquidia Technologies is located next door to the US headquarters of GSK in the US at Triangle Park.

Two companies specialising in a niche market with innovative applications for drug delivery technologies who are both coincidentally partnering with P&G and GSK...?

Fair speculation or not?

11/07/2011
Liquidia and P&G announce collaboration to explore new applications of PRINT®
Source

04/04/2012
RTP firm's nanotechnology will revolutionize medicine - and more
"While Liquidia CEO Neal Fowler believes the technology will transform drug delivery around the world, he says his Resarch Triangle Park company sees greater opportunities beyond medicine. Vaccines are Liquidia’s first target but the company’s platform technology has applications in materials science. Liquidia is now in a a partnership with Proctor & Gamble expected to bring the technology to an array of consumer products. Fowler said he couldn’t discuss details of the P&G deal. But he did say that these kinds of deals are examples of nanotechnology’s broad potential, which will eventually eclipse biotechnology in size and scope." - Full announcement

26/04/2012
During the quarter the relationship with GSK was expanded to include discussions with the GSK Pharmaceutical groups in the US.

20/06/2012
Liquidia Technologies announces collaboration with GlaxoSmithKline
Liquidia Technologies today announced the initiation of a broad, multi-year collaboration with GlaxoSmithKline (GSK), which has acquired exclusive rights to research and develop certain vaccine and inhaled product candidates using the company’s proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology. Liquidia’s PRINT technology is a powerful and versatile nanoparticle technology product development and manufacturing platform that is changing the way companies engineer healthcare products. - Full announcement


__________

Andrew Witty article - eyes on the US - away from Europe

01 November 2012
GSK CEO: Strategic anchors are very very promising
"So I think in terms of pipeline, it's really starting to look very, very exciting. And while we can't dismiss all the risks until we've gone through the regulatory processes and we started to launch the products, there's no question in terms of both numbers and potential scale of opportunity, we've never had a portfolio like this at GSK, and I'm not sure too many other companies have ever had it either." - Strategic anchors are very very promising